array:19 [ "pii" => "S2387020624001700" "issn" => "23870206" "doi" => "10.1016/j.medcle.2024.05.003" "estado" => "S300" "fechaPublicacion" => "2024-05-31" "aid" => "6507" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Med Clin. 2024;162:485-93" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "Immunotherapy in multiple myeloma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "485" "paginaFinal" => "493" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Inmunoterapia en el mieloma múltiple" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2419 "Ancho" => 3127 "Tamanyo" => 404509 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">CAR-T cell collection and mechanism of action. <span class="elsevierStyleItalic">1. Lymphocytapheresis.</span> The patient undergoes an apheresis session in which, by centrifugation of the blood, their mononuclear cells (lymphocytes and monocytes) are extracted. <span class="elsevierStyleItalic">Isolation of T-lymphocytes.</span> The apheresis product is processed to purify the cell population of interest, i.e. the T-lymphocytes. <span class="elsevierStyleItalic">3.</span> The genetic material coding for the CAR receptor (construct) is introduced into the lymphocytes by a retrovirus (lentivirus or retrovirus) or by physical methods (electroporation). The incorporation of this genetic material results in the lymphocyte expressing a chimeric antigenic receptor (CAR), as it combines part of the B-cell receptor (BCR) and part of the T-cell receptor (TCR). The CAR consists of an antigen recognition domain (similar to an immunoglobulin chain, part of the BCR), a transmembrane domain, a co-stimulatory domain and an intracellular signalling domain (CD3, part of the TCR). <span class="elsevierStyleItalic">CAR-T cell expansion.</span> The cells are expanded <span class="elsevierStyleItalic">in vitro</span> until the target cell dose is reached. <span class="elsevierStyleItalic">5. Infusion to the patient.</span> Lymphodepleting chemotherapy, usually a combination of fludarabine and cyclophosphamide, has a dual aim: to reduce the disease burden and to allow further expansion of CAR-T cells <span class="elsevierStyleItalic">in vivo</span>. After administration of the chemotherapy, and allowing time for washout, CAR-T is infused into the patient. <span class="elsevierStyleItalic">6. Target antigen recognition and immune attack.</span> Once the target antigen (in the figure, BCMA) is recognised, the CAR-T cell secretes vesicles loaded with perforins and granzymes. Perforins produce a pore in the cell under attack, allowing the entry of granzymes which, through caspases, ultimately trigger apoptosis of the neoplastic cell. Other mechanisms contributing to tumour cell apoptosis not depicted in the figure are the expression of CAR-T death ligands (e.g. FAS-L) or the release of cytokines and activation of stromal cells. Activation of CAR-T allows for its in vivo expansion, its persistence and a prolonged anti-tumour surveillance over time.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Pedro Asensi Cantó, Mario Arnao Herraiz, Javier de la Rubia Comos" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Pedro" "apellidos" => "Asensi Cantó" ] 1 => array:2 [ "nombre" => "Mario" "apellidos" => "Arnao Herraiz" ] 2 => array:2 [ "nombre" => "Javier" "apellidos" => "de la Rubia Comos" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0025775323007534" "doi" => "10.1016/j.medcli.2023.11.019" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775323007534?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020624001700?idApp=UINPBA00004N" "url" => "/23870206/0000016200000010/v1_202405280655/S2387020624001700/v1_202405280655/en/main.assets" ]
Journal Information
Vol. 162. Issue 10.
Pages 485-493 (May 2024)
Vol. 162. Issue 10.
Pages 485-493 (May 2024)
Review
Immunotherapy in multiple myeloma
Inmunoterapia en el mieloma múltiple
Pedro Asensi Cantó, Mario Arnao Herraiz, Javier de la Rubia Comos
Article information
These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscribe
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail